Monthly Financial Headlines

Overview

This report monitors budget performance based on total prescribing for the whole BNF at ICB, sub-ICB and PCN level for the financial year to date with particular focus on cost and item growth compared to the same period from the previous financial year.

Frequency

Monthly

Data period

April 2024

Price Concessionary Bulletin

Overview

The purpose of this bulletin is to present the predicted cost impact of drug price changes, both through the Price Concessions list and also monthly drug tariff (DT) cost variations. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the NHSBSA Drug Tariff PartVIIIA. An adjustment is also made if necessary to the prescribing data of each drug to account for any difference in dispensing days between the 2 months. Data is presented at region, ICB and SICBL level.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

Frequency

Monthly

Data Period

May 2024 (Drug Tariff), March 2024 (ePACT2 prescribing data)

Monthly Horizon Scanning Report – June 2024

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Shared care protocol – methylphenidate in adults

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Update information

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

Current version: v1.0

Last updated: 12th June 2024

Monthly formulary amendments – May 2024

Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines.  This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.

This edition covers guidance and alerts published in May 2024.

It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Drug Tariff Monitor

Overview

The purpose of this report is to present the predicted cost impact of category A, M and C drug tariff PartVIIIA price changes on primary care spending. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the NHSBSA Drug Tariff PartVIIIA. An adjustment is also made if necessary to the prescribing data of each drug to account for any difference in dispensing days between the 2 months. Data is presented at SICBL and ICB level.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net

Frequency

Quarterly

Data Period

April 2024 (Drug Tariff), February 2024 (ePACT2 Prescribing data)

Prescribing Update Newsletter – May 2024

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition focuses on recent RDTC publications and the dates of our upcoming demo and Q&A sessions on RDTC reports, publications, and resources.

View the preview below on desktop, or click here to download a copy.

Antimicrobial prescribing across primary and secondary care

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees.

This report combines primary and secondary care medicines usage data for antimicrobials. It supports ICBs in the consideration of system-wide ICS medicines data for a complete overview of system prescribing.

Incorporating primary and secondary care prescribing data to better understand the ICS

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees.

A combination of multiple datasets is required for the planning and prioritisation of services, and the allocation of funding in an Integrated Care System (ICS). This report highlights the limitations and challenges of combining primary and secondary care medicines datasets to understand medicines use across an ICS footprint.

Formulary assessment – Calcifediol soft capsules

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.